Michael Needle, MD and Chief Medical Officer of AVEO Oncology goes over why and how Tivozanib (FOTIVDA(R)) was given approval in the European Union for the treatment of advanced renal cell carcinoma.
Tivozanib Approved in EU for Advanced RCC
Advertisement